BRIAN FRANCISCHAPINBRIAN FRANCIS CHAPIN9666CHAPIN, BRIAN FRANCISAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1155 Pressler StHouston77030-3721TXDiagnostic RadiologyGenitourinary Medical OncologyRadiation OncologyMD AndersonLOUIS LPISTERSLOUIS L PISTERS8619PISTERS, LOUIS LProfessorCHRISTOPHER GWOODCHRISTOPHER G WOOD8666WOOD, CHRISTOPHER GProfessorSTEVEN JAYFRANKSTEVEN JAY FRANK8958FRANK, STEVEN JAYProfessor8.005960.00579621235research areas1.87370.034129764coauthor of151.7124.703760similar to11110selected publicationsPATRICIATRONCOSOPATRICIA TRONCOSO8504TRONCOSO, PATRICIAProfessorTHARAKESWARA KBATHALATHARAKESWARA K BATHALA9809BATHALA, THARAKESWARA KAssistant ProfessorCHRISTOPHER JLOGOTHETISCHRISTOPHER J LOGOTHETIS8480LOGOTHETIS, CHRISTOPHER JProfessorDEBORAH AKUBANDEBORAH A KUBAN8889KUBAN, DEBORAH AProfessorANAAPARICIOANA APARICIO9362APARICIO, ANAAssociate ProfessorAuthorship 2294761Authorship 2300631Authorship 230342121514040Chapin BF, Wood CGEuropean urologyThe RENAL nephrometry nomogram: statistically significant, but is it clinically relevant? Eur Urol. 2011 Aug; 60(2):249-51; discussion 251-2.Eur Urol2011-04-16T00:00:002011The RENAL nephrometry nomogram: statistically significant, but is it clinically relevant?21523561Chapin BF, Delacroix SE, Wood CGInternational journal of clinical oncologyThe role of lymph node dissection in renal cell carcinoma. Int J Clin Oncol. 2011 Jun; 16(3):186-94.Int J Clin Oncol2011-04-28T00:00:002011The role of lymph node dissection in renal cell carcinoma.21606286Chapin BF, Delacroix SE, Wood CGAJR. American journal of roentgenologyRenal cell carcinoma: what the surgeon and treating physician need to know. AJR Am J Roentgenol. 2011 Jun; 196(6):1255-62.AJR Am J Roentgenol2011-06-01T00:00:002011Renal cell carcinoma: what the surgeon and treating physician need to know.Authorship 2450983Authorship 2558011Authorship 2559176Authorship 2570822Authorship 2593903Authorship 259425214510271Oyelese Y, Tchabo JG, Chapin B, Nair A, Hanson P, McLaren RJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in MedicineConservative management of uterine rupture diagnosed prenatally on the basis of sonography. J Ultrasound Med. 2003 Sep; 22(9):977-80.J Ultrasound Med2003-09-01T00:00:002003Conservative management of uterine rupture diagnosed prenatally on the basis of sonography.21367518Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis VEuropean urologyThe impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun; 59(6):912-8.Eur Urol2011-02-23T00:00:002011The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.21621907Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CGEuropean urologySafety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011 Nov; 60(5):964-71.Eur Urol2011-05-25T00:00:002011Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.21849197Delacroix SE, Chapin BF, Chen JJ, Nogueras-Gonzalez GM, Tamboli P, Matin SF, Wood CGThe Journal of urologyCan a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma? J Urol. 2011 Oct; 186(4):1236-41.J Urol2011-08-17T00:00:002011Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma?22045173Delacroix SE, Chapin BF, Wood CGThe Urologic clinics of North AmericaThe role of lymph node dissection in renal cell carcinoma. Urol Clin North Am. 2011 Nov; 38(4):419-28, vi.Urol Clin North Am2011-11-01T00:00:002011The role of lymph node dissection in renal cell carcinoma.23601185Wirth GJ, Psutka SP, Chapin BF, Wu S, Wu CL, Dahl DMBJU internationalMidterm oncological outcomes of laparoscopic vs open radical prostatectomy (RP). BJU Int. 2013 Jul; 112(2):190-7.BJU Int2013-04-19T00:00:002013Midterm oncological outcomes of laparoscopic vs open radical prostatectomy (RP).Authorship 267574317445670Eisner BH, Feldman AS, Chapin BF, Dretler SPUrology"Blind coning"--using the Stone Cone for removal of intramural ureteral calculi. Urology. 2007 Apr; 69(4):773-5.Urology2007-04-01T00:00:002007"Blind coning"--using the Stone Cone for removal of intramural ureteral calculi.Authorship 2787811Authorship 2969531Authorship 303964226048432Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SFUrologyRadical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. Urology. 2015 Jul; 86(1):10-5.Urology2015-06-03T00:00:002015Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status.26178396Chapin BFAsian journal of andrologyOptimal management of prostate cancer with lethal biology--state-of-the-art local therapy. Asian J Androl. 2015 Nov-Dec; 17(6):888-91.Asian J Androl2015-11-01T00:00:002015Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy.74Professor10Assistant Professor21Chair14Associate Professor26059275Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim JBJU internationalDisease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.BJU Int2015-07-04T00:00:002015Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.Authorship 37401312Authorship 844634Authorship 847861Authorship 850963Authorship 852029Authorship 858404Authorship 860149Authorship 860964Authorship 866328Cytoreductive nephrectomy. 109-122.Cytoreductive nephrectomyEuropean UrologyPatterns of Care for Prostate Cancer Patients. European Urology. Patterns of Care for Prostate Cancer PatientsAsian Journal of AndrologyOptimal management of prostate cancer with lethal biology - State-of-the-art local therapy. Asian Journal of Andrology. 17:888-891.Optimal management of prostate cancer with lethal biology - State-of-the-art local therapyEuropean UrologyTreatment of the Primary Tumor in Metastatic Prostate Cancer. European Urology. Treatment of the Primary Tumor in Metastatic Prostate CancerFuture OncologyThe role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncology. 12:687-699.The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancerEuropean UrologyReply to Lu Yang, Shi Qiu and Qiang Wei Letter to the Editor re. European Urology. 71:e51.Reply to Lu Yang, Shi Qiu and Qiang Wei Letter to the Editor reJournal of Clinical OncologyImproved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. Journal of Clinical Oncology. 34:2835-2842.Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancerClinical Genitourinary CancerNeoadjuvant Systemic Therapy before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity. Clinical Genitourinary Cancer. 14:130-138.Neoadjuvant Systemic Therapy before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical MorbidityD011467Anatomy28510800.656645ProstateD011471Disorders75057370.293776Prostatic NeoplasmsD044584Disorders781370.887894Carcinoma, DuctalD011468Procedures1719530.689614ProstatectomyD017430Chemicals & Drugs2059890.731545Prostate-Specific AntigenAuthorship 9044764Authorship 90455910Authorship 9053409Authorship 9060843Authorship 90844511Authorship 91451110Authorship 9149641Authorship 9174512Authorship 9174552Authorship 9177162Authorship 91783111Authorship 9184445Authorship 9188783Authorship 9231365Authorship 92320610Authorship 9236071Authorship 9236302Authorship 9239627Authorship 9286481Authorship 9293907Authorship 9294902Authorship 9303043Authorship 9308907Authorship 93138513Authorship 93191816Authorship 9346198Authorship 9385166Authorship 940220326003223Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F, Novara G, Smaldone MC, Sooriakumaran P, Wiklund PN, Chapin BFEuropean urologyTreatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol. 2016 05; 69(5):775-87.Eur Urol2015-05-21T00:00:002015Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.26558524Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BFClinical genitourinary cancerNeoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer. 2016 Apr; 14(2):130-8.Clin Genitourin Cancer2015-10-24T00:00:002015Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System.26839141Ristau BT, Cahn D, Uzzo RG, Chapin BF, Smaldone MCFuture oncology (London, England)The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncol. 2016 Mar; 12(5):687-99.Future Oncol2016-02-03T00:00:002016The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer.27461403Bayne CE, Williams -B, Chapin BFEuropean urologyReply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87. Eur Urol. 2017 02; 71(2):e51.Eur Urol2016-07-25T00:00:002016Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87.27325855Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJJournal of clinical oncology : official journal of the American Society of Clinical OncologyImproved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 08 20; 34(24):2835-42.J Clin Oncol2016-06-20T00:00:002016Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.27815080Williams SB, Chapin BFEuropean urologyPatterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom? Eur Urol. 2017 05; 71(5):738-739.Eur Urol2016-11-01T00:00:002016Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom?28190749Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BFUrologic oncologyRole of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 04; 35(4):125-134.Urol Oncol2017-02-09T00:00:002017Role of radical prostatectomy in metastatic prostate cancer: A review.28099688Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LA, Kim SP, Hoffman KE, Giordano SH, Chapin BFCancerDiscerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. Cancer. 2017 05 01; 123(9):1617-1624.Cancer2017-01-18T00:00:002017Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.28550942Metcalfe MJ, Chapin BFUrologyEditorial Comment. Urology. 2017 08; 106:151-152.Urology2017-05-24T00:00:002017Editorial Comment.28552614Reichard CA, Chapin BFEuropean urologyLocal Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders? Eur Urol. 2017 09; 72(3):352-353.Eur Urol2017-05-25T00:00:002017Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders?28941030Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DABJU internationalQuality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548.BJU Int2017-10-17T00:00:002017Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort.28922341Chapin BF, Bellmunt JCurrent opinion in urology'Working toward understanding oligo and polymetastatic prostate cancer'. Curr Opin Urol. 2017 11; 27(6):532.Curr Opin Urol2017-11-01T00:00:002017'Working toward understanding oligo and polymetastatic prostate cancer'.29230008Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, Wang X, Tapia EMLN, Davis JW, Troncoso PProstate cancer and prostatic diseasesPositive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer Prostatic Dis. 2018 06; 21(2):221-227.Prostate Cancer Prostatic Dis2017-12-11T00:00:002017Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer.29230009Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BFProstate cancer and prostatic diseasesThe use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2018 04; 21(1):4-21.Prostate Cancer Prostatic Dis2017-12-11T00:00:002017The use of PET/CT in prostate cancer.28710901Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim JBJU internationalBaseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76.BJU Int2017-08-16T00:00:002017Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.28964658Altok M, Achim MF, Matin SF, Pettaway CA, Chapin BF, Davis JWUrologic oncologyA decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol. 2018 01; 36(1):13.e19-13.e25.Urol Oncol2017-09-28T00:00:002017A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents.29395953Kukreja JB, Thompson IM, Chapin BFUrologic oncologyOrganizing a clinical trial for the new investigator. Urol Oncol. 2019 05; 37(5):336-339.Urol Oncol2018-02-01T00:00:002018Organizing a clinical trial for the new investigator.29446205Altok M, Babaian K, Achim MF, Achim GC, Troncoso P, Matin SF, Chapin BF, Davis JWBJU internationalSurgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. BJU Int. 2018 07; 122(1):66-75.BJU Int2018-03-25T00:00:002018Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.29439879Reichard C, Chapin BFEuropean urology focusCan Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy. Eur Urol Focus. 2017 12; 3(6):524-525.Eur Urol Focus2018-02-10T00:00:002018Can Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy.29219275Cartapatti M, Machado RD, Muller RL, Magnabosco WJ, Santos AC, Chapin BF, Melani A, Talvane A, Tobias-Machado M, Faria EFInternational braz j urol : official journal of the Brazilian Society of UrologySynchronous abdominal tumors: is combined laparoscopic surgery in a single approach a safe option? Int Braz J Urol. 2018 May-Jun; 44(3):483-490.Int Braz J Urol2018-05-01T00:00:002018Synchronous abdominal tumors: is combined laparoscopic surgery in a single approach a safe option?29988098Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JWProstate cancer and prostatic diseasesCost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 11; 21(4):524-532.Prostate Cancer Prostatic Dis2018-07-09T00:00:002018Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research.30253446Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJInternational journal of urology : official journal of the Japanese Urological AssociationImpact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):998-1004.Int J Urol2018-09-25T00:00:002018Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.30179617Gregg JR, Lopez DS, Reichard C, Zheng J, Wu W, Ye Y, Chapin B, Kim J, Daniel CR, Davis JThe Journal of urologyCoffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. J Urol. 2019 02; 201(2):308-314.J Urol2019-02-01T00:00:002019Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance.30423193Sundi D, Tosoian JJ, Nyame YA, Alam R, Achim M, Reichard CA, Li J, Wilkins L, Schwen Z, Han M, Davis JW, Klein EA, Schaeffer EM, Stephenson AJ, Ross AE, Chapin BFCancerOutcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer. 2019 02 01; 125(3):391-397.Cancer2018-11-13T00:00:002018Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.30653804Reichard CA, Nyame YA, Sundi D, Tosoian J, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Davis JW, Chapin BFBJU internationalDoes time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome? BJU Int. 2019 08; 124(2):282-289.BJU Int2019-02-10T00:00:002019Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?30458585Patel DN, Chapin BF, Freedland SJInternational journal of urology : official journal of the Japanese Urological AssociationResponse to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):1005.Int J Urol2018-11-20T00:00:002018Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.30363448Jaber Y, Reichard CA, Chapin BFTranslational andrology and urologyEmerging role of cytoreductive prostatectomy in patients with metastatic disease. Transl Androl Urol. 2018 Sep; 7(Suppl 4):S505-S513.Transl Androl Urol2018-09-01T00:00:002018Emerging role of cytoreductive prostatectomy in patients with metastatic disease.30679782Gregg JR, Zheng J, Lopez DS, Reichard C, Browman G, Chapin B, Kim J, Davis J, Daniel CRBritish journal of cancerDiet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. Br J Cancer. 2019 02; 120(4):466-471.Br J Cancer2019-01-25T00:00:002019Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance.PathologyUrologyBaylor College of MedicineAuthorship 942992130904395Chapin BFUrologic oncologyClinical Trials in Urology. Urol Oncol. 2019 05; 37(5):303-304.Urol Oncol2019-03-20T00:00:002019Clinical Trials in Urology.Authorship 943794929656854Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BFEuropean urologyRadical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. 2018 08; 74(2):140-143.Eur Urol2018-04-12T00:00:002018Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.Authorship 945094230956769Sundi D, Chapin BFOncotargetVery-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy. Oncotarget. 2019 Mar 08; 10(20):1870-1871.Oncotarget2019-03-08T00:00:002019Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy.Authorship 945920831009137Reichard CA, Hoffman KE, Tang C, Williams SB, Allen PK, Achim MF, Kuban DA, Chapin BFBJU internationalRadical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU Int. 2019 11; 124(5):811-819.BJU Int2019-05-29T00:00:002019Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment.Authorship 946614931076357Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BFEuropean urology focusPrediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus. 2021 01; 7(1):71-77.Eur Urol Focus2019-05-08T00:00:002019Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design.Authorship 9491301331200839Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EMEuropean urology oncologyMulti-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264.Eur Urol Oncol2019-01-04T00:00:002019Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging.Authorship 9510544Authorship 951249331266732Ranasinghe WKB, Reichard CA, Bathala T, Chapin BFEuropean urology focusManagement of cT4 Prostate Cancer. Eur Urol Focus. 2020 03 15; 6(2):221-226.Eur Urol Focus2019-06-30T00:00:002019Management of cT4 Prostate Cancer.31248604Ranasinghe WKB, Reichard CA, Chapin BFEuropean urologyTreatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care. Eur Urol. 2019 Nov; 76(5):543-545.Eur Urol2019-06-25T00:00:002019Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.Authorship 954498231451157Reichard CA, Chapin BFUrologyEditorial Comment. Urology. 2019 09; 131:174.Urology2019-09-01T00:00:002019Editorial Comment.Authorship 9552391131501508Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BFProstate cancer and prostatic diseasesImpact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178.Prostate Cancer Prostatic Dis2019-09-09T00:00:002019Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer.Authorship 961293731742674Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DACancerContemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer. 2020 02 01; 126(3):506-514.Cancer2019-11-19T00:00:002019Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends.Authorship 975151631899230Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim JUrologyDetermining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 04; 138:91-97.Urology2019-12-30T00:00:002019Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort.Authorship 976302531977495Chen B, Bathala TK, Xu G, Teyateeti A, Chapin BF, Tang C, Tu SM, Macapinlac HA, Lu YClinical nuclear medicineComparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clin Nucl Med. 2020 May; 45(5):349-355.Clin Nucl Med2020-05-01T00:00:002020Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.Authorship 9792482Authorship 9794089Authorship 979761332176456Ranasinghe W, Chapin BF, Kim IY, Sooriakumaran P, Lawrentschuk NBJU internationalThe cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int. 2020 06; 125(6):792-800.BJU Int2020-04-07T00:00:002020The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.32191331Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang CJAMA network openAssociation of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open. 2020 03 02; 3(3):e201255.JAMA Netw Open2020-03-02T00:00:002020Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer.32130049Bhargava P, Ravizzini G, Chapin BF, Kundra VAJR. American journal of roentgenologyImaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? AJR Am J Roentgenol. 2020 06; 214(6):1248-1258.AJR Am J Roentgenol2020-03-04T00:00:002020Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed?Authorship 9863031032238575Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma PScience translational medicineNeoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).Sci Transl Med2020-04-01T00:00:002020Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.Authorship 9866561532259468Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Allaf ME, Davis JW, Chapin BFThe Journal of urologyDowngrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer. J Urol. 2020 10; 204(4):748-753.J Urol2020-04-07T00:00:002020Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.Authorship 987487832298794Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE, Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BDPractical radiation oncologyCosts and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol. 2020 Jul - Aug; 10(4):282-292.Pract Radiat Oncol2020-04-13T00:00:002020Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data.Authorship 98839914Authorship 988462732353391Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang CInternational journal of radiation oncology, biology, physicsIncreased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):982-985.Int J Radiat Oncol Biol Phys2020-04-27T00:00:002020Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers.32357283Shapiro DD, Gregg JR, Lim AH, Nogueras-Gonz?lez GM, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW, Ward JFBJU internationalComparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int. 2021 03; 127(3):340-348.BJU Int2020-06-29T00:00:002020Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance.Authorship 9901242Authorship 9902171132446432Surasi DSS, Chapin B, Tang C, Ravizzini G, Bathala TKSeminars in ultrasound, CT, and MRImaging and Management of Prostate Cancer. Semin Ultrasound CT MR. 2020 Apr; 41(2):207-221.Semin Ultrasound CT MR2020-02-18T00:00:002020Imaging and Management of Prostate Cancer.32453443Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW, Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BFCancerPatterns of metastases of prostatic ductal adenocarcinoma. Cancer. 2020 08 15; 126(16):3667-3673.Cancer2020-05-26T00:00:002020Patterns of metastases of prostatic ductal adenocarcinoma.Authorship 9999204Authorship 999921432960678Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MSThe Journal of urologyAdvanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021 Jan; 205(1):22-29.J Urol2020-09-22T00:00:002020Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.32960679Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MSThe Journal of urologyAdvanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan; 205(1):14-21.J Urol2020-09-22T00:00:002020Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.Authorship 1002738533048621Hussain M, Lin D, Saad F, Vapiwala N, Chapin BF, Sandler H, Evans CP, Carducci MA, Sachdev SJournal of clinical oncology : official journal of the American Society of Clinical OncologyNewly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? J Clin Oncol. 2021 01 01; 39(1):13-16.J Clin Oncol2020-10-13T00:00:002020Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?Authorship 10046644Authorship 1004846733160843Westerman ME, Tabakin AL, Sexton WJ, Chapin BF, Singer EAUrologic oncologyImpact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs. Urol Oncol. 2021 06; 39(6):357-364.Urol Oncol2020-09-30T00:00:002020Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs.33173205Wilkins LJ, Tosoian JJ, Sundi D, Ross AE, Grimberg D, Klein EA, Chapin BF, Nyame YANature reviews. UrologySurgical management of high-risk, localized prostate cancer. Nat Rev Urol. 2020 12; 17(12):679-690.Nat Rev Urol2020-11-10T00:00:002020Surgical management of high-risk, localized prostate cancer.Authorship 10064671733279304Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BFEuropean urologyDuctal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021 02; 79(2):298-306.Eur Urol2020-12-03T00:00:002020Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.Authorship 1006867733316361Tang C, Lei X, Smith GL, Pan HY, Hoffman KE, Kumar R, Chapin BF, Shih YT, Frank SJ, Smith BDInternational journal of radiation oncology, biology, physicsInfluence of Geography on Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1286-1295.Int J Radiat Oncol Biol Phys2020-12-13T00:00:002020Influence of Geography on Prostate Cancer Treatment.Authorship 1008381333411364Gregg JR, Zhang X, Chapin BF, Ward JF, Kim J, Davis JW, Daniel CRCancerAdherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer. 2021 03 01; 127(5):720-728.Cancer2021-01-07T00:00:002021Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort.DANIELHAMSTRADANIEL HAMSTRA16519HAMSTRA, DANIELProfessorAuthorship 1013361233676955Altok M, Chapin BF, Matin SF, Achim MF, Gregg JR, Davis JWUrologyTherapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology. 2021 09; 155:144-151.Urology2021-03-05T00:00:002021Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase.Authorship 101382611Authorship 1014146333721334Wilkins LJ, Tosoian JJ, Reichard CA, Sundi D, Ranasinghe W, Alam R, Schwen Z, Reddy C, Allaf M, Davis JW, Chapin BF, Ross AE, Klein EA, Nyame YACancerOncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. Cancer. 2021 05 01; 127(9):1425-1431.Cancer2021-03-15T00:00:002021Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.33741867Baiomy A, Schellingerhout D, Chapin BF, Weinberg JS, Raza SM, Macapinlac H, Ravizzini GNuclear medicine communicationsRate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. Nucl Med Commun. 2021 Jul 01; 42(7):755-762.Nucl Med Commun2021-07-01T00:00:002021Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer.Authorship 10151158Authorship 10151331333824032Oke O, Ranasinghe W, Tang C, Shaaban S, Xiao L, Reichard CA, Anscher MS, Chapin BF, Aparicio AEuropean urologyImpact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma. Eur Urol. 2021 09; 80(3):389-390.Eur Urol2021-04-03T00:00:002021Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.33824525Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BFNature reviews. UrologyOptimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021 06; 18(6):337-358.Nat Rev Urol2021-04-06T00:00:002021Optimizing the diagnosis and management of ductal prostate cancer.Authorship 1016402733858748Klaassen Z, Scarpato KR, Ristau BT, Stratton KL, Porten SP, Smaldone MC, Chapin BF, Psutka SPUrologic oncologyResearch highlights of the 2020 society of urologic oncology young urologic oncologists' program. Urol Oncol. 2021 08; 39(8):452-454.Urol Oncol2021-04-12T00:00:002021Research highlights of the 2020 society of urologic oncology young urologic oncologists' program.true1ProfessorProfessorAuthorship 1023776334159100McCormick BZ, Chery L, Chapin BFTranslational andrology and urologyContemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer. Transl Androl Urol. 2021 May; 10(5):2178-2187.Transl Androl Urol2021-05-01T00:00:002021Contemporary outcomes following robotic prostatectomy for locally advanced and metastatic prostate cancer.Authorship 1025627534280440Geskin AA, Westney OL, Graber WJ, Smith Iii TG, Chapin BF, Gregg JRUrologyComplications Of Peri-Operative Ureteral Catheter Placement: Experience at A Major Cancer Center. Urology. 2022 06; 164:88-93.Urology2021-07-16T00:00:002021Complications Of Peri-Operative Ureteral Catheter Placement: Experience at A Major Cancer Center.Authorship 1030035834536949Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou EEuropean journal of cancer (Oxford, England : 1990)Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267.Eur J Cancer2021-09-15T00:00:002021Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer.Authorship 1034105434775795Cooperberg MR, Lin DW, Morgan TM, Chapin BF, Chen RC, Eggener SEThe Journal of urologyActive Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264.J Urol2021-11-15T00:00:002021Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.Authorship 104049811Authorship 1041092535212559Yadav D, Hwang H, Qiao W, Upadhyay R, Chapin BF, Tang C, Aparicio A, Lopez-Olivo MA, Kang SK, Macapinlac HA, Bathala TK, Surasi DSRadiology. Imaging cancer18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer. 2022 03; 4(2):e210091.Radiol Imaging Cancer2022-03-01T00:00:00202218F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis.35076303Ranasinghe WKB, Troncoso P, Surasi DS, Ibarra Rovira JJ, Bhosale P, Szklaruk J, Kokorovic A, Wang X, Elsheshtawi M, Zhang M, Aparicio A, Chapin BF, Bathala TKRadiologyDefining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. Radiology. 2022 04; 303(1):110-118.Radiology2022-01-25T00:00:002022Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI.Authorship 1044578435475154Shapiro DD, Davis JW, Williams WH, Chapin BF, Ward JF, Pettaway CA, Gregg JRBJUI compassIncreased body mass index is associated with operative difficulty during robot-assisted radical prostatectomy. BJUI Compass. 2022 Jan; 3(1):68-74.BJUI Compass2021-09-27T00:00:002021Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomy.Authorship 1050737935840112Ryckman JM, Thomas TV, Wang M, Wu X, Siva S, Spratt DE, Slotman B, Pal S, Chapin BF, Fitzal F, Soran A, Bex A, Louie AV, Lehrer EJ, Zaorsky NGInternational journal of radiation oncology, biology, physicsLocal Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):919-935.Int J Radiat Oncol Biol Phys2022-07-15T00:00:002022Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis.Authorship 1066227236948506Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SKJournal for immunotherapy of cancerImmune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 03; 11(3).J Immunother Cancer2023-03-01T00:00:002023Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).Authorship 106802826Authorship 10684825Authorship 10689061437057728Andring LM, Abu-Gheida I, Bathala T, Yoder AK, Manzar GS, Maldonado JA, Frank SJ, Choi S, Nguyen QN, Hoffman K, McGuire SE, Mok H, Aparicio A, Chapin BF, Tang CBJU internationalDefinitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int. 2023 09; 132(3):307-313.BJU Int2023-04-25T00:00:002023Definitive local therapy for T4 prostate cancer associated with improved local control and survival.37126069Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM, SPOTLIGHT Study GroupThe Journal of urologyDiagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). J Urol. 2023 08; 210(2):299-311.J Urol2023-04-26T00:00:002023Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).37022702Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PGJAMA oncologyAddition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 06 01; 9(6):825-834.JAMA Oncol2023-06-01T00:00:002023Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.Authorship 1069841337194136Andrews JR, Sood A, Chapin BFThe Journal of urologyPoint-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer. J Urol. 2023 08; 210(2):242-243.J Urol2023-05-17T00:00:002023Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer.Authorship 107298310Authorship 107412615Authorship 1074474837350185Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DMThe Journal of urologyDiagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply. J Urol. 2023 09; 210(3):411-412.J Urol2023-06-23T00:00:002023Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.37414702Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF, LIGHTHOUSE Study GroupEuropean urologyDiagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Eur Urol. 2023 10; 84(4):361-370.Eur Urol2023-07-05T00:00:002023Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).37416959Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DMThe Journal of urologyReply by Authors. J Urol. 2023 Aug; 210(2):310-311.J Urol2023-07-07T00:00:002023Reply by Authors.Authorship 10773122237586362Wang K, Kumar T, Wang J, Minussi DC, Sei E, Li J, Tran TM, Thennavan A, Hu M, Casasent AK, Xiao Z, Bai S, Yang L, King LM, Shah V, Kristel P, van der Borden CL, Marks JR, Zhao Y, Zurita AJ, Aparicio A, Chapin B, Ye J, Zhang J, Gibbons DL, Grand Challenge PRECISION Consortium, Sawyer E, Thompson AM, Futreal A, Hwang ES, Wesseling J, Lips EH, Navin NECellArchival single-cell genomics reveals persistent subclones during DCIS progression. Cell. 2023 08 31; 186(18):3968-3982.e15.Cell2023-08-15T00:00:002023Archival single-cell genomics reveals persistent subclones during DCIS progression.Authorship 1084953937914379Kiani K, Kim SP, Pessoa RR, Gershman B, Gonzalez C, Molina E, Warren A, DaSilva RD, Chapin B, Ballon-Landa EUrology practiceAssociation of Frailty and Complications Following Prostate Biopsy: Results From a Population-Based, Privately Insured Cohort. Urol Pract. 2024 Jan; 11(1):117-122.Urol Pract2023-11-01T00:00:002023Association of Frailty and Complications Following Prostate Biopsy: Results From a Population-Based, Privately Insured Cohort.Authorship 10865661038212510Fang AM, Jackson J, Gregg JR, Chery L, Tang C, Surasi DS, Siddiqui BA, Bathala T, Chapin BFCurrent treatment options in oncologySurgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer. Curr Treat Options Oncol. 2024 Jan; 25(1):66-83.Curr Treat Options Oncol2024-01-03T00:00:002024Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer.Authorship 1087825438262868Gregg JR, Magill R, Fang AM, Chapin BF, Davis JW, Adibi M, Ch?ry L, Papadopoulos J, Pettaway C, Pisters L, Ward JF, Hahn AW, Daniel CR, Bhaskaran J, Zhu K, Guerrero M, Zhang M, Troncoso PUrologic oncologyThe association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urol Oncol. 2024 Apr; 42(4):116.e1-116.e7.Urol Oncol2024-01-22T00:00:002024The association of body mass index with tumor aggression among men undergoing radical prostatectomy.Authorship 10896744Authorship 10896764Authorship 1089675438421253Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RCThe Journal of urologySalvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024 Apr; 211(4):509-517.J Urol2024-02-29T00:00:002024Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.38421243Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RCThe Journal of urologySalvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr; 211(4):518-525.J Urol2024-02-29T00:00:002024Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.38421252Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RCThe Journal of urologySalvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr; 211(4):526-532.J Urol2024-02-29T00:00:002024Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professor24411278Chapin BF, McGuire SE, Aparicio AEuropean urologyIs treatment of the primary tumor in metastatic prostate cancer justified? Eur Urol. 2014 Jun; 65(6):1067-8.Eur Urol2013-12-17T00:00:002013Is treatment of the primary tumor in metastatic prostate cancer justified?Department of Radiation OncologyRadiation Oncology